Marker Therapeutics (MRKR) has released an update.
Marker Therapeutics, Inc. has made a significant breakthrough in its Phase 1 APOLLO study, with their MT-601 treatment showing promising results in patients with lymphoma who have relapsed from or are ineligible for anti-CD19 CAR T cell therapy. One patient achieved a complete response for over nine months, surpassing previous therapies, while two others also showed positive responses, including complete and partial remissions. These results, presented at the 11th Global Summit on Hematologic Malignancies, suggest MT-601 could be a durable alternative for lymphoma treatment.
For further insights into MRKR stock, check out TipRanks’ Stock Analysis page.
